MedTrace Logo

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors

NCT06231550 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-08-07

No results posted yet for this study

Summary

This is a phase I clinical study to evaluate safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Axl inhibitor FC084CSA in patients with advanced malignant solid tumors who have failed standard anti-cancer treatment.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

FC084CSA tablets

FC084CSA accelerated doses at 100mg QD, and then started the conventional "3+3" design from 200mg QD.

Sponsors & Collaborators

  • FindCure Biosciences (ZhongShan) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-03-18
Completion
2025-03-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06231550 on ClinicalTrials.gov